INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. for alleged securities fraud, with investors who purchased shares between October 10, 2023, and December 26, 2025, potentially entitled to compensation [1]. Group 1: Lawsuit Details - The lawsuit claims that Inovio made false and misleading statements regarding its CELLECTRA device manufacturing and the likelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [1]. - It is alleged that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [1]. - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the misleading public statements made by the defendants [1]. Group 2: Legal Representation - The Rosen Law Firm, which is leading the class action, emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [1]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone, and has been recognized for its achievements in securities class action settlements [1]. - Investors interested in joining the class action can do so without upfront fees through a contingency fee arrangement [1].